175 related articles for article (PubMed ID: 21849469)
1. Epithelial protein-tyrosine phosphatase 1B contributes to the induction of mammary tumors by HER2/Neu but is not essential for tumor maintenance.
Balavenkatraman KK; Aceto N; Britschgi A; Mueller U; Bence KK; Neel BG; Bentires-Alj M
Mol Cancer Res; 2011 Oct; 9(10):1377-84. PubMed ID: 21849469
[TBL] [Abstract][Full Text] [Related]
2. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
3. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis.
Julien SG; Dubé N; Read M; Penney J; Paquet M; Han Y; Kennedy BP; Muller WJ; Tremblay ML
Nat Genet; 2007 Mar; 39(3):338-46. PubMed ID: 17259984
[TBL] [Abstract][Full Text] [Related]
4. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.
Meyer DS; Aceto N; Sausgruber N; Brinkhaus H; Müller U; Pallen CJ; Bentires-Alj M
Oncogene; 2014 Jan; 33(3):398-402. PubMed ID: 23318421
[TBL] [Abstract][Full Text] [Related]
6. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor.
Krishnan N; Koveal D; Miller DH; Xue B; Akshinthala SD; Kragelj J; Jensen MR; Gauss CM; Page R; Blackledge M; Muthuswamy SK; Peti W; Tonks NK
Nat Chem Biol; 2014 Jul; 10(7):558-66. PubMed ID: 24845231
[TBL] [Abstract][Full Text] [Related]
7. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
8. Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles.
Schade B; Lam SH; Cernea D; Sanguin-Gendreau V; Cardiff RD; Jung BL; Hallett M; Muller WJ
Cancer Res; 2007 Aug; 67(16):7579-88. PubMed ID: 17699761
[TBL] [Abstract][Full Text] [Related]
9. Egr-1 is required for neu/HER2-induced mammary tumors.
Oh S; Kim H; Nam K; Shin I
Cell Signal; 2018 May; 45():102-109. PubMed ID: 29408223
[TBL] [Abstract][Full Text] [Related]
10. Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.
Berman-Golan D; Granot-Attas S; Elson A
Cancer Metastasis Rev; 2008 Jun; 27(2):193-203. PubMed ID: 18231724
[TBL] [Abstract][Full Text] [Related]
11. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.
Croci S; Nanni P; Palladini A; Nicoletti G; Grosso V; Benegiamo G; Landuzzi L; Lamolinara A; Ianzano ML; Ranieri D; Dall'Ora M; Iezzi M; De Giovanni C; Lollini PL
Breast Cancer Res; 2015 May; 17(1):70. PubMed ID: 25997501
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ
Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486
[TBL] [Abstract][Full Text] [Related]
17. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells and cells of origin in MMTV-Her2/neu-induced mammary tumorigenesis.
Lo PK; Chen H
Oncogene; 2013 Mar; 32(10):1338-40. PubMed ID: 23045276
[No Abstract] [Full Text] [Related]
19. Protein tyrosine phosphatase 1B restrains mammary alveologenesis and secretory differentiation.
Milani ES; Brinkhaus H; Dueggeli R; Klebba I; Mueller U; Stadler M; Kohler H; Smalley MJ; Bentires-Alj M
Development; 2013 Jan; 140(1):117-25. PubMed ID: 23154416
[TBL] [Abstract][Full Text] [Related]
20. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
